Technology Bundle ID
NCI-E-042-2009

Immunogenic Peptide from NGEP Protein for Developing Prostate Cancer Vaccines

Applications
Therapeutics
Lead Inventors
Jeffrey Schlom (NCI)
Co-Inventors
Ira Pastan (NCI)
Kwong-Yok Tsang (NCI)
Development Status
Pre-clinical (in vivo)
ICs
NCI

The NGEP protein is only present in the prostate and is typically overexpressed on prostate cancer cells. Hence, as a novel prostate tumor-associated antigen (TAA) it is a good target for developing active immunotherapies to kill prostate cancer cells. For example, NGEP could be used in a vaccine to activate an individual's immune system to recognize and kill NGEP-expressing prostate cancer cells. However, TAAs typically are not very effective in inciting an immune response. This can be overcome by identifying portions (epitopes) of the TAA that are more immunologically active.

Investigators at the NIH have identified a small peptide fragment of the NGEP protein (NGEP CTL peptide epitope) that is very effective in activating cytotoxic lymphocytes causing them to destroy prostate cancer cells and has great potential for development of a variety of active immunotherapy strategies, such as vector-based cancer vaccines, to treat and prevent prostate cancer. In addition, it could be used for developing sensitive immunoassays for measuring the immune response of a prostate cancer patient during immunotherapy.

Commercial Applications
  • Peptide cancer vaccine
  • Vector-based cancer vaccine
  • Liposome-based cancer vaccine
  • Cellular cancer vaccine
  • In vitro diagnostic for monitoring the immune response of prostate cancer patients during cancer vaccine trials
Competitive Advantages
  • Small biologic therapeutic
  • Can be chemically synthesized or produced recombinantly
  • DNA encoded peptide allows molecular engineering
  • Can be used as a tumor antigen with the clinically proven TRICOM-based vaccine technology

Request More Info

Licensing Contact: